MA44759B1 - Forme polymorphe de n-(6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl)-6-(trifluorométhyl)pyridine-2-carboxamide - Google Patents

Forme polymorphe de n-(6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl)-6-(trifluorométhyl)pyridine-2-carboxamide

Info

Publication number
MA44759B1
MA44759B1 MA44759A MA44759A MA44759B1 MA 44759 B1 MA44759 B1 MA 44759B1 MA 44759 A MA44759 A MA 44759A MA 44759 A MA44759 A MA 44759A MA 44759 B1 MA44759 B1 MA 44759B1
Authority
MA
Morocco
Prior art keywords
hydroxypropan
indazol
methylsulfonyl
carboxamide
trifluoromethyl
Prior art date
Application number
MA44759A
Other languages
English (en)
Other versions
MA44759A (fr
Inventor
Johannes Platzek
Tobias Thaler
Nicolas Guimond
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA44759A publication Critical patent/MA44759A/fr
Publication of MA44759B1 publication Critical patent/MA44759B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86—Hydrazides; Thio or imino analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des formes cristallines de n-{6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl}-6-(trifluorométhyl)pyridine-2-carboxamide, des procédés pour leur préparation, des compositions pharmaceutiques les comprenant et leur utilisation pour lutter contre certains troubles.
MA44759A 2016-04-29 2017-04-25 Forme polymorphe de n-(6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl)-6-(trifluorométhyl)pyridine-2-carboxamide MA44759B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16167652 2016-04-29
PCT/EP2017/059767 WO2017186703A1 (fr) 2016-04-29 2017-04-25 Forme polymorphe de n-{6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl}-6-(trifluorométhyl)pyridine-2-carboxamide

Publications (2)

Publication Number Publication Date
MA44759A MA44759A (fr) 2019-03-06
MA44759B1 true MA44759B1 (fr) 2024-01-31

Family

ID=55860769

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44759A MA44759B1 (fr) 2016-04-29 2017-04-25 Forme polymorphe de n-(6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl)-6-(trifluorométhyl)pyridine-2-carboxamide

Country Status (42)

Country Link
US (2) US10759758B2 (fr)
EP (4) EP3448848B1 (fr)
JP (2) JP7068188B2 (fr)
KR (2) KR102373220B1 (fr)
CN (3) CN109071489B (fr)
AR (1) AR108245A1 (fr)
AU (2) AU2017256626B2 (fr)
CA (1) CA3022324C (fr)
CL (2) CL2018003087A1 (fr)
CO (2) CO2018011622A2 (fr)
CU (1) CU20180131A7 (fr)
DK (2) DK3448846T3 (fr)
DO (1) DOP2018000237A (fr)
EA (2) EA038035B1 (fr)
EC (1) ECSP18081437A (fr)
ES (2) ES2883298T3 (fr)
FI (1) FI3448848T3 (fr)
GE (1) GEP20217214B (fr)
HR (2) HRP20211072T1 (fr)
HU (2) HUE064389T2 (fr)
IL (2) IL262414B2 (fr)
JO (2) JOP20170099B1 (fr)
LT (2) LT3448848T (fr)
MA (1) MA44759B1 (fr)
MX (2) MX380032B (fr)
MY (2) MY190319A (fr)
NI (1) NI201800112A (fr)
PE (1) PE20190107A1 (fr)
PH (1) PH12018502289B1 (fr)
PL (2) PL3448848T3 (fr)
PT (2) PT3448848T (fr)
RS (2) RS64928B1 (fr)
SA (1) SA518400333B1 (fr)
SG (2) SG11201808108XA (fr)
SI (2) SI3448846T1 (fr)
SV (1) SV2018005775A (fr)
TN (1) TN2018000352A1 (fr)
TW (2) TWI649314B (fr)
UA (2) UA124103C2 (fr)
UY (2) UY37216A (fr)
WO (2) WO2017186703A1 (fr)
ZA (1) ZA201808057B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
CN109071489B (zh) 2016-04-29 2020-07-10 拜耳医药股份有限公司 吲唑的合成
HUE049331T2 (hu) 2016-04-29 2020-09-28 Bayer Pharma AG Indazolok szintézise
AU2017273771B2 (en) * 2016-06-01 2022-09-29 Bayer Pharma Aktiengesellschaft Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
RU2743170C2 (ru) * 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
KR20210024543A (ko) 2018-06-25 2021-03-05 치아타이 티안큉 파마수티컬 그룹 주식회사 IRAK4 억제제로서의 이소티아졸로[5,4-d]피리미딘 화합물
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CN110981903A (zh) * 2019-11-28 2020-04-10 南京正济医药研究有限公司 一种艾日布林中间体化合物提高光学纯度的精制方法
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
CA3191387A1 (fr) 2020-09-30 2022-04-07 Nobell Foods, Inc. Proteines de lait recombinantes et compositions les comprenant
CN114469979B (zh) * 2021-12-15 2024-04-09 安徽贝克生物制药有限公司 一种核糖核苷类似物的药物组合物、吸入剂及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
CA2641884A1 (fr) 2006-02-10 2007-08-16 Summit Corporation Plc Traitement de la dystrophie musculaire de duchenne
EP2045253A4 (fr) 2006-06-29 2013-01-23 Nissan Chemical Ind Ltd DÉRIVÉ D'ACIDE alpha-AMINÉ ET PRODUIT PHARMACEUTIQUE QUI LE COMPREND EN TANT QUE MATIÈRE ACTIVE
MX2009002377A (es) 2006-09-07 2009-03-13 Biogen Idec Inc Derivados de indazol como moduladores de cinasa asociados con el receptor de interleucina-1.
EP2486925A4 (fr) 2009-10-09 2014-03-19 Mitsubishi Tanabe Pharma Corp Agent thérapeutique de l'infarctus cérébral
WO2011153588A1 (fr) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Inhibiteurs de polymérase virale
BR112013015460B1 (pt) 2010-12-20 2022-01-25 Merck Serono S.A. Derivados de indazolil triazol, kit, e composição farmacêutica
WO2013106254A1 (fr) 2012-01-11 2013-07-18 Dow Agrosciences Llc Compositions pesticides et procédés qui leur sont associés
US9126984B2 (en) 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
EP3066090A1 (fr) 2013-11-08 2016-09-14 iTeos Therapeutics Dérivés de 4-(indol-3-yl)pyrazole, compositions pharmaceutiques et procédés d'utilisation
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
US10160753B2 (en) * 2014-01-10 2018-12-25 Aurigene Discovery Technologies Limited Indazole compounds as IRAK4 inhibitors
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
HK1249509A1 (zh) 2015-07-15 2018-11-02 Aurigene Discovery Technologies Limited 作为irak-4抑制剂的吲唑及氮杂吲唑化合物
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (fr) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinaisons de copanlisib
HUE049331T2 (hu) 2016-04-29 2020-09-28 Bayer Pharma AG Indazolok szintézise
CN109071489B (zh) 2016-04-29 2020-07-10 拜耳医药股份有限公司 吲唑的合成
RU2743170C2 (ru) 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных
AU2017273771B2 (en) 2016-06-01 2022-09-29 Bayer Pharma Aktiengesellschaft Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases

Also Published As

Publication number Publication date
TW201738230A (zh) 2017-11-01
EA201892430A1 (ru) 2019-05-31
SG11201808108XA (en) 2018-10-30
JP2019514923A (ja) 2019-06-06
SV2018005775A (es) 2019-02-07
KR20180137496A (ko) 2018-12-27
LT3448848T (lt) 2023-11-27
UA123169C2 (uk) 2021-02-24
RS62112B1 (sr) 2021-08-31
EP3448848B1 (fr) 2023-09-27
JP7068188B2 (ja) 2022-05-16
JOP20170099B1 (ar) 2022-03-14
EP4275755A2 (fr) 2023-11-15
ES2883298T3 (es) 2021-12-07
IL262414B1 (en) 2023-06-01
TWI657084B (zh) 2019-04-21
UY37216A (es) 2018-06-29
CA3022332A1 (fr) 2017-11-02
MY187184A (en) 2021-09-09
CN109071489A (zh) 2018-12-21
KR20180137497A (ko) 2018-12-27
EP4275754A2 (fr) 2023-11-15
HUE064389T2 (hu) 2024-03-28
EA038035B1 (ru) 2021-06-25
ES2966772T3 (es) 2024-04-24
AU2017256626A1 (en) 2018-10-11
BR112018072242A2 (pt) 2019-04-09
EP4275754A3 (fr) 2023-12-27
UA124103C2 (uk) 2021-07-21
PT3448846T (pt) 2021-08-19
MY190319A (en) 2022-04-13
CA3022324C (fr) 2024-10-29
WO2017186703A1 (fr) 2017-11-02
ECSP18081437A (es) 2018-11-30
CO2018011622A2 (es) 2018-11-22
US20190112270A1 (en) 2019-04-18
IL262659A (en) 2018-12-31
US10759758B2 (en) 2020-09-01
NZ746526A (en) 2023-08-25
FI3448848T3 (fi) 2023-12-21
MX2018013235A (es) 2019-02-13
BR112018072246A2 (pt) 2019-02-12
MX2018013234A (es) 2019-02-13
PH12018502289B1 (en) 2022-04-06
AU2017257211A1 (en) 2018-10-11
AU2017256626B2 (en) 2021-05-27
CA3022324A1 (fr) 2017-11-02
PL3448846T3 (pl) 2021-12-20
RS64928B1 (sr) 2023-12-29
AU2017257211B2 (en) 2021-05-27
DK3448846T3 (da) 2021-08-16
HRP20231454T1 (hr) 2024-03-01
EP3448848A1 (fr) 2019-03-06
CL2018003087A1 (es) 2019-02-22
MA44759A (fr) 2019-03-06
SI3448848T1 (sl) 2024-01-31
US20190106407A1 (en) 2019-04-11
LT3448846T (lt) 2021-07-26
UY37215A (es) 2017-11-30
PE20190107A1 (es) 2019-01-15
MX380032B (es) 2025-03-11
CN109415340B (zh) 2021-10-12
CU20180131A7 (es) 2019-06-04
WO2017186689A1 (fr) 2017-11-02
AR108245A1 (es) 2018-08-01
CN109071489B (zh) 2020-07-10
JP6954924B2 (ja) 2021-10-27
SA518400333B1 (ar) 2022-06-05
TWI649314B (zh) 2019-02-01
HUE056460T2 (hu) 2022-02-28
IL262414A (en) 2018-12-31
CN109415340A (zh) 2019-03-01
TN2018000352A1 (en) 2020-06-15
GEP20217214B (en) 2021-01-25
JP2019514922A (ja) 2019-06-06
CL2018003088A1 (es) 2019-01-25
CO2018011644A2 (es) 2018-11-13
DOP2018000237A (es) 2018-11-15
KR102373017B1 (ko) 2022-03-11
TW201738232A (zh) 2017-11-01
PH12018502289A1 (en) 2019-07-15
NZ746469A (en) 2023-08-25
SG11201808566WA (en) 2018-11-29
DK3448848T3 (da) 2023-12-18
IL262659B (en) 2021-05-31
EP4275755A3 (fr) 2023-12-27
EA201892415A1 (ru) 2019-05-31
EP3448846B1 (fr) 2021-05-26
PL3448848T3 (pl) 2024-03-11
NI201800112A (es) 2019-08-29
MX383591B (es) 2025-03-14
HRP20211072T1 (hr) 2021-10-01
EP3448846A1 (fr) 2019-03-06
US10501417B2 (en) 2019-12-10
KR102373220B1 (ko) 2022-03-11
ZA201808057B (en) 2023-05-31
CN113185457A (zh) 2021-07-30
SI3448846T1 (sl) 2021-09-30
JOP20170100B1 (ar) 2022-03-14
IL262414B2 (en) 2023-10-01
PT3448848T (pt) 2024-01-02

Similar Documents

Publication Publication Date Title
MA44759B1 (fr) Forme polymorphe de n-(6-(2-hydroxypropan-2-yl)-2-[2-(méthylsulfonyl)éthyl]-2h-indazol-5-yl)-6-(trifluorométhyl)pyridine-2-carboxamide
PH12016502523A1 (en) Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
WO2015132799A3 (fr) Nouveaux composés hétérocycliques
TN2018000359A1 (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide.
MX2021007184A (es) Formas cristalinas del derivado de 4-pirimidinsulfamida aprocitentan.
MA37379A1 (fr) Formes polymorphes de l'acide -2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
CL2015001529A1 (es) Compuestos derivados de indol carboxamida, antagonistas del receptor p2x7; composicion farmaceutica y su uso para la prevencion o tratamiento de enfermedades neurodegenerativas y neuroinflamatorias, enfermedades oseas y articulares, enfermedades cardiovaculares, entre otras.
EA201692008A1 (ru) Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
PH12018500859A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease
EA201991021A1 (ru) Соединения конденсированных бициклических пиридинов и их применение в качестве модуляторов ampa-рецептора
WO2014193647A3 (fr) Composés alcényles et procédés d'utilisation
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
EP3248603A4 (fr) Composition pharmaceutique destinée à la prévention, au traitement ou au ralentissement de la maladie d'alzheimer ou de la démence contenant un agent de type récepteur couplé à une protéine g 19 comme principe actif
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
EP3404020A4 (fr) Dérivé de pyridinol ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique contenant celui-ci utilisé comme principe actif
SI1853232T1 (sl) Stabilna kristalna oblika bifeprunoks-mezilata, njegove dozirne oblike in postopki za njihovo uporabo
EA202092787A1 (ru) Синтез типифарниба
TH149015A (th) สารประกอบที่คุมกิจกรรมของ c-fms และ/หรือ c-kit และการใช้งานสำหรับสิ่งนั้น